A. T. Nguyen1, K. M. Samadzadeh1, K. C. Chun1, A. E. Rona1, A. M. Afkhami1, P. Ghosh3,4, E. S. Lee1,2 3University Of California – Davis,Urology,Sacramento, CA, USA 4VA Northern California Health Care System,Mather, CA, USA 1VA Northern California Health Care System,Surgery,Mather, CA, USA 2University Of California – Davis,Surgery,Sacramento, CA, USA
Introduction:
MiR-155 has been reported to inhibit ras homology member A (RhoA) in multiple cell lines. RhoA acts as a molecular switch in a signaling cascade that induces cytoskeletal reorganization within cells. Several studies suggest increased RhoA activity is linked with enhanced cellular transmigration through the endothelium. Increased monocyte activity was found to be correlated to abdominal aortic aneurysm (AAA) disease. However, the relationship between RhoA and AAA disease is not fully understood. This study examines whether miR-155 is associated with higher RhoA activity in patients with AAA.
Methods:
Monocytes were isolated from patient blood and lysed for Rhotekin-RBD Assay and western blotting. BCA assay measured protein concentration and 5ug of protein was loaded onto SDS PAGE gels. The subsequent PVDF membrane was incubated with a rabbit RhoA antibody and developed using ECL substrate. Images were scanned and processed using Image J software. MicroRNAs were isolated from serum and quantified using Agilent BioAnalyzer 2100. MiR-155 levels were assessed using quantitative PCR with Exiqon LNA primers and normalized using the 2-ΔΔCT method. Student’s t-test was used to compare AAA and control groups for statistical analysis.
Results:
Patients with large AAAs (>5.5cm in diameter, lanes 1, 3, and 4 ) displayed higher RhoA activity (n=3) versus small AAAs (<5cm in diameter, lane 2, 5, and 6) (n=3) (Figure 1a). Lane 7 was THP-1 used for data normalization. Rho-GTP activity was then quantified using Image J software, values are represented as relative change in expression (*p<.05) (Figure 1b). Q-PCR results showed miR-155 was down-regulated in serum, displaying a 3-fold decrease (*p< .05) in AAA subjects (n=5) versus non-AAA controls (n=4) (Figure 1c).
Conclusion:
Patients with large AAA have increased RhoA activity compared to small AAA. Additionally, decreased serum miR-155 is associated with greater RhoA activity in patients with large AAA. Pharmacological regulation of these microRNAs may attenuate monocyte RhoA activity in patients with AAA.